USE OF A THRESHOLD OF INTERLEUKIN-10 AND IL-10/IL-6 RATIO IN OCULAR SAMPLES FOR THE SCREENING OF VITREORETINAL LYMPHOMA
Overview
Authors
Affiliations
Purpose: To determine a threshold for interleukin (IL)-10 and IL-10/IL-6 ratio in the aqueous humor (AH) and the vitreous for the screening of vitreoretinal lymphoma (VRL).
Methods: One hundred nineteen patients for whom IL-10 and IL-6 in the AH and/or vitreous had been measured were included: 16 patients with a final diagnosis of VRL and 103 patients with final diagnosis of uveitis. Groups were compared according to IL-10 and IL-6 levels and demographic data.
Results: In patients with VRL (Group 1), mean IL-10 values were 5,636 pg/mL, and in patients with uveitis (Group 2), 6.7 pg/mL in the vitreous and 190 pg/mL in Group 1 and 8.6 pg/mL in the AH. In Group 1, the mean IL-10/IL-6 ratio was 29.02 in the vitreous and 10.9 in the AH; in Group 2, ratio was 0.1 in both humors. These values were significantly different between patients with VRL and with uveitis (P < 0.001). A cutoff of 65 pg/mL and 30 pg/mL IL-10 in the vitreous and AH, respectively, was associated with sensitivity of 93% and 78%, respectively, and specificity of 100% and 97%, respectively. A ratio higher than 1 in the vitreous had sensitivity of 93% and specificity of 100%.
Conclusion: Vitreoretinal lymphoma diagnosis is difficult, and tools like interleukin measurements in AH and vitreous can make it easier. The use of a cutoff for IL-10 and IL-10/IL-6 ratio could allow for an earlier diagnosis that may improve prognosis.
Mainguy A, Soussain C, Touitou V, Bennedjai A, Kodjikian L, Ghesquieres H Bone Marrow Transplant. 2024; 60(3):297-304.
PMID: 39562715 PMC: 11893470. DOI: 10.1038/s41409-024-02477-y.
Diagnosis of primary vitreoretinal lymphoma masquerading infectious retinitis by retinal biopsy.
Nguyen N, Khan F, Cannon A, Huang Y, Kim L, Xu R J Ophthalmic Inflamm Infect. 2024; 14(1):8.
PMID: 38324143 PMC: 10850038. DOI: 10.1186/s12348-024-00389-y.
Liquid biopsy: creating opportunities in brain space.
Trivedi R, Bhat K Br J Cancer. 2023; 129(11):1727-1746.
PMID: 37752289 PMC: 10667495. DOI: 10.1038/s41416-023-02446-0.
Kim M, Suh H, Park Y, Park Y Sci Rep. 2023; 13(1):4478.
PMID: 36934118 PMC: 10024690. DOI: 10.1038/s41598-023-31414-0.
Kang H, Tao Y Int J Ophthalmol. 2022; 15(12):1893-1902.
PMID: 36536977 PMC: 9729077. DOI: 10.18240/ijo.2022.12.01.